Swedish Orphan Biovitrum AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 1.54%

Swedish Orphan Biovitrum AB (publ) (SOBI) has an Asset Resilience Ratio of 1.54% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Swedish Orphan Biovitrum AB (publ) working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr1.04 Billion

≈ $112.03 Million USD Cash + Short-term Investments

Total Assets

Skr67.43 Billion

≈ $7.26 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Swedish Orphan Biovitrum AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SOBI current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Swedish Orphan Biovitrum AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Swedish Orphan Biovitrum AB (publ) (SOBI) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr1.04 Billion	1.54%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr1.04 Billion	1.54%

Asset Resilience Insights

Limited Liquidity: Swedish Orphan Biovitrum AB (publ) maintains only 1.54% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Swedish Orphan Biovitrum AB (publ) Industry Peers by Asset Resilience Ratio

Compare Swedish Orphan Biovitrum AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Beijing Tongrentang Co Ltd SHG:600085	Drug Manufacturers - Specialty & Generic	0.50%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	5.50%
Neuland Laboratories Limited NSE:NEULANDLAB	Drug Manufacturers - Specialty & Generic	9.65%
China Resources Double-Crane Pharmaceutical Co Ltd SHG:600062	Drug Manufacturers - Specialty & Generic	1.18%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.01%

Annual Asset Resilience Ratio for Swedish Orphan Biovitrum AB (publ) (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Swedish Orphan Biovitrum AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.54%	Skr1.04 Billion ≈ $112.03 Million	Skr67.43 Billion ≈ $7.26 Billion	-0.14pp
2024-12-31	1.68%	Skr1.27 Billion ≈ $136.67 Million	Skr75.44 Billion ≈ $8.12 Billion	+0.46pp
2023-12-31	1.22%	Skr904.00 Million ≈ $97.28 Million	Skr74.03 Billion ≈ $7.97 Billion	-1.35pp
2022-12-31	2.58%	Skr1.35 Billion ≈ $145.50 Million	Skr52.50 Billion ≈ $5.65 Billion	+0.45pp
2021-12-31	2.13%	Skr1.04 Billion ≈ $111.49 Million	Skr48.66 Billion ≈ $5.24 Billion	+1.29pp
2020-12-31	0.84%	Skr404.00 Million ≈ $43.48 Million	Skr48.28 Billion ≈ $5.20 Billion	-0.78pp
2019-12-31	1.61%	Skr737.00 Million ≈ $79.31 Million	Skr45.66 Billion ≈ $4.91 Billion	-15.84pp
2018-12-31	17.45%	Skr3.00 Billion ≈ $322.71 Million	Skr17.18 Billion ≈ $1.85 Billion	+3.89pp
2017-12-31	13.56%	Skr1.48 Billion ≈ $159.11 Million	Skr10.90 Billion ≈ $1.17 Billion	+5.68pp
2016-12-31	7.88%	Skr786.00 Million ≈ $84.59 Million	Skr9.97 Billion ≈ $1.07 Billion	+6.16pp
2009-12-31	1.72%	Skr48.36 Million ≈ $5.20 Million	Skr2.81 Billion ≈ $301.92 Million	-6.26pp
2008-12-31	7.98%	Skr205.83 Million ≈ $22.15 Million	Skr2.58 Billion ≈ $277.52 Million	-12.27pp
2007-12-31	20.25%	Skr394.57 Million ≈ $42.46 Million	Skr1.95 Billion ≈ $209.67 Million	-5.12pp
2006-12-31	25.38%	Skr527.21 Million ≈ $56.74 Million	Skr2.08 Billion ≈ $223.59 Million	--

pp = percentage points

About Swedish Orphan Biovitrum AB (publ)

ST:SOBI Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$16.36 Billion

Skr152.03 Billion SEK

Market Cap Rank

#1528 Global

#22 in Sweden

Share Price

Skr439.60

Change (1 day)

-1.92%

52-Week Range

Skr272.60 - Skr480.00

All Time High

Skr480.00